Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD HPV immunization study
PACTR202507884495103Phase 2Not yet recruiting
- Sponsor
- International Vaccine Institute
- Start
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine and Normal Saline-Benha University in human papillomavirus infection (2 arms), sponsored by International Vaccine Institute. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccineNormal Saline-Benha University
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on PACTR202507884495103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202507884495103.